University of Salford

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer. His appointment reflects the progress of 20Med’s development activities of polymeric nanoparticles (PNPs) in the delivery of mRNA vaccines targeting infectious diseases. Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi. He has held global strategic positions and operational roles, leading vertically integrated teams from Drug Discovery through Clinical Development, Regulatory Affairs, Market Access, Industrial Affairs, Medical Affairs and Commercialization, most recently as Chief Executive Officer of RQ Bio. Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors. Hugo holds a B.Sc. in Chemistry from the University of Salford and studied Finance at London Business School and Leadership at Duke University. Commenting on his appointment, Hugo Fry stated: “There is a clear need for more diverse delivery technologies to unlock the full potential of mRNA vaccines. As an alternative to lipid nanoparticles (LNPs), 20Med’s unique PNP platform has the potential to address some of the barriers faced today by developers of mRNA-based vaccines. I am looking forward to working with the team at 20Med to pursue strategic partnerships to bring PNP-delivered vaccines into the clinic as soon as possible.” Michiel Lodder, Ph.D., CEO of 20Med Therapeutics, added: “The expansion of our leadership team marks another milestone for 20Med in a year that already saw significant progress in terms of financing and partnering activities with our CEPI and Touchlight agreements. We are also preparing several publications, which will further substantiate the capabilities of our PNP platform and showcase its benefits over LNP-based solutions to mRNA delivery. Overall, we enter 2024 in a strong position to advance our mission to establish the leading non-LNP delivery platform for mRNA-based vaccines.” “We are thrilled to have Hugo join the 20Med Therapeutics leadership team in a crucial period for the company and with a clear window of opportunity ahead of us. His experience and network in the vaccine industry will greatly support 20Med in establishing its PNP platform as a leading non-LNP solution with distinct features and benefits for the development of mRNA vaccines,” commented Michel Baijot, Ph.D., Chairman of the Board of 20Med Therapeutics. +++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++ About 20Med Therapeutics At 20Med Therapeutics, we develop RNA-based vaccines based on proprietary bioresponsive polymer nanoparticles. Our non-LNP delivery platform offers distinct advantages in terms of development speed, ease of manufacture, stability, cost of goods, and freedom to operate. We have partnered with CEPI to develop thermostable vaccines for influenza, tackling the barriers to wider application and distribution of mRNA-based vaccines using LNPs as the delivery vehicle. 20Med Therapeutics applies pioneering biomaterial and medical science and is located in Enschede and Leiden in the Netherlands. For further information, please visit: https://20medtx.com or contact info@20medtx.com Contact 20Med TherapeuticsCharlotte VoorhoeveDirector Strategy & OperationsPhone +31 61 205 86 43E-mail: info@20medtx.com For media Mario BrkuljValency CommunicationsPhone: +49 160 9352 9951E-mail: mbrkulj@valencycomms.eu Attachment Hugo_Fry_by_Barry_Braunstein_Photography

DALLAS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Prof. Paul Chadwick as Executive Vice President of the Company’s United Kingdom subsidiary. Prof. Chadwick is an experienced clinical scientist and wound care key opinion leader (KOL) with an impressive body of work including a substantial and impactful publication record, particularly in the domain of diabetic wound management. He will be responsible for the international market expansion of the Company’s DeepView® wound imaging technology in the United Kingdom, Europe, Middle East and Africa (EMEA), all of which are geographic areas where Prof. Chadwick has extensive clinical networks, significant experience and has enjoyed previous successes. “Paul brings over fifteen years of invaluable expertise in the medical devices and technology sectors to our team. The Royal College of Podiatry is an extremely prestigious and important organization where Paul most recently served for over six years in senior executive capacities, including CEO. We are highly confident that his addition will significantly enhance our efforts in advancing the widespread adoption of the DeepView® System,” said Niko Pagoulatos, the Company’s COO. “Spectral AI continues to strengthen its leadership team and Paul’s experience in diabetic foot ulcers and clinical wound management will contribute to our growth and enhance our capacity to innovate.” Prof. Chadwick’s impressive journey stretches across clinical, academic and business disciplines. In his previous roles at the Royal College of Podiatry, Prof. Chadwick led all the clinical, educational and financial aspects of the organization. In addition, he has held multiple leadership positions such as consultant podiatrist at The National Health Service (NHS), and Managing Director at Curativo Wound Care Consultancy, where he has served companies such as 3M, Molnlycke Health Care, Smith & Nephew, Advancis, Thornton & Ross, Essity and many others. In his capacity as a prominent authority in wound care, Prof. Chadwick fulfills critical roles on advisory boards and exemplifies best practices in the field. Furthermore, he generously imparts his knowledge as an adjunct professor at Birmingham City University, where he teaches in the Health and Life Sciences Department. Prof. Chadwick said, “Coming from a traditional wound care background with an emphasis on DFU and other chronic wounds, and having collaborated with leading commercial organizations in the wound care arena at a national and global level, with a focus on EMEA, I am delighted to contribute to Spectral AI’s mission and success, and I believe that the DeepView® System represents the future of wound healing management. As we move forward, this technology has the potential to transform patient wound care at multiple levels.” Prof. Chadwick earned his Ph.D. with a thesis on aspects of painful diabetic neuropathy at the University of Salford. He earned his M.Sc. with a focus on foot ulceration from Manchester Metropolitan University and holds an undergraduate degree in Science Honors from the University of Brighton. About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com. Forward Looking Statements Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Contacts: Investors:Spectral AI, Inc.Christine Marks VP Marketing and Commercialization ir@spectral-ai.com The Equity Group Devin Sullivan Managing Director dsullivan@equityny.com Conor Rodriguez Analyst crodriguez@equityny.com Media: Russo Partners David Schull Russo Partners (858) 717-2310 david.schull@russopartnersllc.com Guillermo Ruiz, M.D., Ph.D. Russo Partners (646) 218-4604 guillermo.ruiz@russopartnersllc.com

Bats may have lived in caves and used soundwaves to navigate much earlier than first thought. Of all the mammals, bats have one of the poorest fossil records, with palaeontologists estimating that about 80 per cent of it is missing. This has made it difficult to pinpoint exactly when they first began to fly, or began roosting in caves, or developed their unique way of 'seeing' their surroundings in the dark using sound -- called echolocation. But a near-perfectly preserved bat's skull discovered by French palaeontologists in a cave that dates back about 50 million years has shed new light on what we thought we knew about this ancient, hypothetical creature. Emeritus Professor Sue Hand from UNSW Sydney's School of Biological Earth and Environmental Sciences is a leading palaeontologist with expertise in bat evolution. She led an analysis of the skull, published today in the journal Current Biology, that involved Dr Jacob Maugoust and Professor Maeva Orliac from University of Montpellier in France, and Professor Robin Beck from the University of Salford, UK. Prof. Hand says prior to the discovery of this skull -- which was among 23 separate fossilised individuals found in the cave belonging to the extinct species Vielasia sigei -- only fragments or completely flattened skeletons of early bats had existed in the fossil record. "We don't know very much about the beginnings of bats because we don't have the missing links like we do, say, between dinosaurs and modern birds," she says. "The oldest bat fossil is about 57 million years old, and it's a single tooth from a site in Portugal -- that's all we know about it. The first bats are all just known from fragmentary fossils, mostly teeth. When bats appear in the fossil record a little later, about 52 million years ago, some are wonderfully complete bats, but they're flattened." While these flattened specimens are, in Prof. Hand's words, "beautifully preserved," the fact that they've been flattened by layers of rock deposited over millions of years makes it difficult to decide with conviction, the exact positioning of bones in their three-dimensional anatomy. And when it comes to determining whether a fossil is from a species of bat that is already using echolocation, detailed and precise anatomy of the skull is crucial. "In modern bats, between the voice box and the ear, there are some bones called the hyoid bones. In all modern bats that echolocate, one of these bones directly contacts the middle ear bones and appears to be involved in transmitting high frequency sound. "But in the flattened fossils, while we can see these various bones, there is a question about their precise relationships to each other. This has led to a lot of debate among scientists about whether or not a species used echolocation." Uncrushed skull But in the case of Vielasia sigei, not only is the skull almost entirely intact, but it has been preserved in limestone in its original three-dimensional shape which the scientists describe as 'uncrushed'. "In this particular bat, we can see more directly what's going on deeper, in the inner ear," Prof. Hand says. "We took fine measurements of that inner ear bone and compared it with that in the bats that do echolocate today and bats that don't, and it sits in the middle of the ones that echolocate." Not all bats echolocate, Prof. Hand explains. Flying foxes regularly seen in the Sydney night sky around the Botanical Gardens, Centennial Park and the Royal National Park rely on their very good eyesight to navigate and find fruit, without echolocation. Meanwhile, Sydney microbats such as the Eastern Bentwing Bat, Gould's Wattled Bat and the Chocolate Wattled Bat, are well known for navigating and catching insects using feedback from the high frequency sound they emit. While Prof. Hand stops short of concluding that Vielasia sigei used echolocation with 100 per cent certainty, she says the new evidence is compelling. "It's very convincing that the type of echolocation some of these early bats used was indistinguishable from what many echolocating bats use today, and at 50 million years ago, this is well ahead of whales developing this ability. "Prior to this find, we were only really certain that echolocation developed in the modern families of bats." Back to the bat cave In all, there were 400 fossil bones and teeth discovered by the French team in the cave in south-western France, which represented 23 individuals. Vielasia -- which is not a direct ancestor of today's bats but may have been closely related to it -- was only a small bat, with the uncrushed skull measuring only 1.8 cm long. "There were 23 of these wonderful little bats living in a cave, which also makes it the oldest cave-dwelling bat in the world that we know of," says Prof. Hand. "We didn't think that these early bats actually lived in caves. The information had been that they lived in trees around lakes and in forests which stretched right up to both poles because the Earth was very warm at this time." But when these greenhouse conditions started to deteriorate later in the early Eocene period -- around 50 million years ago and about the same time that this bat was living -- there were much more wildly fluctuating changes in temperature. "So it could be that this bat lived in a cave because this is much more stable environment." Inspiration Whether or not the analysis of the uncrushed Vielasia skull has settled the echolocation debate about early bats, Prof. Hand hopes that it will inspire further exploration of the fossil record. "We think some of the characteristics of this bat would have also characterised the last common ancestor for modern bats. So it's exciting, and it is actually going to be an important specimen that people will get a lot of information from and use in their own analyses."